Table of Contents

ABSTRACT

The prevalence of heart failure (HF) continues to be high, and it is also increasing in developing countries [1, 2]. Despite increased availability of optimal medical therapy, refractory HF is a common finding, leading to a globalization of the disease requiring global response. The emergence of cardiac resynchronization therapy (CRT) has brought a new paradigm in the management of HF [3-5]. CRT has been the most promising device therapy in mild-to-severe HF over the past two decades [4, 5], has improved the prognosis of HF and has been incorporated into therapeutic guidelines. This communication aims to highlight the utility and necessity of CRT in the treatment of CHF in patients refractory to pharmacotherapy.